Table 9.
Demographic details, anatomical and functional outcomes, and the most common complication of the largest studies published on the different types of keratoprosthesis devices preferred in patients with dry eye disease
| Type of Kpro | Study, year | Number of eyes | Most common etiology No. of eyes (%) | Duration of follow-up in months | Anatomical outcomes | Functional outcomes | Most common complication No. of eyes (%) |
|---|---|---|---|---|---|---|---|
| MOOKP | Iannetti et al.[23] 2022 | 82 | SJS: 58 (70.7%) | 328 (28.8-624) | 94%a | BCVA ≥20/200: @5 years: 85% @10 years: 81% @30 years: 55% | Glaucoma De novo: 41/62 (66%) |
| Boston type II | Lee et al.[31] 2016 | 48 | SJS: 20 (41.7%) MMP: 20 (41.7%) | 70.2 (6-237.6) | 50%a | BCVA ≥20/200: 37.5% | RPM: 29/48 (60.4%) |
| MICOF | Wang et al.[39] 2015 | 90 | Alkali burns: 51 (56.6%) | 58.22 (1-145) | 96.67%a | BCVA ≥20/200: 81.11% | Corneal leak or melt: 36/90 (40%) |
| Tibial | Charoenrook et al.[43] 2016 | 113 | Chemical and thermal burns: 36 (31.8%) | 504 (1-38.8) | 69.5% @ 5 years 53.5% @ 10 years 42.8% @ 15 years | BCVA ≥20/20 33%@ 5 years 19.2%@ 10 years | Keratoprosthesis extrusion: 31/113 (27.4%) |
| LVP | Basu et al.[45] 2018 | 58 | SJS: 49 (84.4%) | 28 (12-67) | 81%a | BCVA ≥20/400: 37.6%@ 3 years | RPM: 25/58 (43%) |
| Lux | Bakshi et al.[46] 2020 | 9 | SJS: 5 (55.5%) | 18.7 (7-28) | 100%a | BCVA ≥20/200: 100% | RPM: 3/9 (33.3%) |
| Pintucci | Maskati and Maskati[48] 2006 | 31 | Chemical burns: 11 (35.4%) | 38.4 (6-84) | 100%a | BCVA ≥20/200: 13% | Glaucoma: 3/31 (9.7%) |
BCVA=best-corrected visual acuity, MICOF=the Moscow eye microsurgery complex in Russia, MMP=mucous membrane pemphigoid, MOOKP=modified osteo-odonto keratoprosthesis, RPM=retroprosthetic membrane, SJS=Stevens-Johnson syndrome. aAnatomical outcomes were defined as the number of eyes that retained the keratoprosthesis at last follow-up